Navigation Links
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Date:7/23/2008

ascular risk in patients with osteoarthritis, and possibly other pathologies associated with the use of anti-inflammatory drugs. Further studies, however, are necessary.

"This study suggests a new, important application that could offer routine screening and monitoring for the risk of cardiovascular adverse events to physicians and patients," Dr. Giannitsis said.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com .

References

(1) Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. The Concentration of N-Terminal Pro-B-type Natriuretic Peptide Predicts the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial. Clin Chem. May 1, 2008 (electronic publication ahead of print), to be published in July 2008.

All trademarks used or mentio
'/>"/>

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...s treated at the initial dose in an ongoing Phase ...d decline after three days , , Conference Call ...ewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc....e first cohort of an ongoing Phase Ib clinical tri...cleoside polymerase inhibitor. ANA598 was very we...
(Date:1/7/2009)..., Tenn., Jan. 7 Scienti...ct a high likelihood of relapse in children with a...searchers caution that further research is needed ...1 or IKAROS, lead to leukemia relapse, the find...agnostic tests to assess the risk of treatment fai...
(Date:1/7/2009)...CK, Md., Jan. 7 ImQuest Life Scien...n IND application to the Food and Drug Administrat...ad pyrimidinedione HIV inhibitor IQP-0410. ImQuest...he first quarter of 2009. IQP-0410 is a novel smal...s a nonnucleoside reverse transcriptase inhibitor ...
(Date:1/7/2009)..., Jan. 7 Tiantan Puhua Hospital St... the worldwide leader in using stem cells to effec...ay six new globally experienced additions to its m...d the hospital,s treatment capabilities for growin...six senior doctors include the distinguished Dr. J...
Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 1Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 2Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 3Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 4Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 5Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 6Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 7Pivotal Data Showed SYMBICORT 28R 29 Improved Lung Function in Adults with COPD 3367 8The American Journal of Nursing honors Jean and Ric Edelman 28137 1The American Journal of Nursing honors Jean and Ric Edelman 28137 2The American Journal of Nursing honors Jean and Ric Edelman 28137 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 1Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 2Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 3Hagens Berman Sobol Shapiro 3A Class Action Filed Against Spectranetics 28134 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 1mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 2mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 3mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 4mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 5mtvU and The Jed Foundation Ask Students How Are You A Friend 3F 28131 6
... protein,protects human pancreatic cancer cells fr... of the body,s natural defenses against,out-of-con... Texas,M. D. Anderson Cancer Center report in the ...otein tissue transglutaminase, known by the abbrev...rs at M. D. Anderson and,elsewhere to be overexpre...
...cal studies have,shown (1) similar rates of neurol... patients being treated with Tamiflu compared to,t...urthermore,recent data derived from US health ins...00 influenza patients treated with Tamiflu,and ove...ve shown,that the Tamiflu treated patients showed ...
Other Medicine Technology:Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 2New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 3New Data from the US and Japan Support: No Established Causal Link,Between Neuropsychiatric Symptoms and Treatment with Tamiflu US,Databases Indicate Psychiatric Symptoms Lower in Influenza Patients,Taking Tamiflu Versus Those Not Taking Tamiflu 4
(Date:1/8/2009)..., Md., Jan. 8 Hanger Or...announce that throughout the fourth quarter of 200... Center, Rocky Mountain Orthotic-Prosthetics Cente...nc., First Coast Orthotics & Prosthetics, and ...uisitions add patient care centers to existing mar...
(Date:1/8/2009)...FRANCISCO, Jan. 8 Mediva... David Hung, M.D., president and chief,executive ...an Healthcare,Conference on Wednesday, January 14...ancis Hotel in San Francisco. , Dr. Hung wi...cal,development programs for Dimebon for Alzheime...
(Date:1/8/2009)...E, Md., Jan. 8 A new ed...ice and guidance on drugs, biological products and...search and Quality,s Centers for Education and Res...ed network of more than a dozen leading research c...Advisory Information Network ( CHAIN ) http://www...
(Date:1/8/2009)...ne Promoted to Principal. Christine Siu and Jason...NNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan...., a health care venture capital firm that invests ...today announced the promotion of three members of ... to Principal. Christine Siu and Jason Brown have...
Breaking Medicine News(10 mins):Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
...be treated by using state-of-the-art gene therapy ...field have developed a way of blasting DNA into ce...in caused when the heart is starved of blood due t...t may precede a heart attack. In many cases this i...
...f inheritable genes to enable people to produce mo...ttitudes to family relationships and on being huma...spiring parents with inheritable diseases hold out...offers them the possibility of avoiding passing di...
...p forward in dissecting the pathways and mechanism...hers of Yale University have seen a break through ...e adult onset Type II Diabetes mellitus. The...g a gene that produces the enzyme called Akt2 or /...
...rchers, patients suffering from Angina may have so...rapy or doses of antibiotics. Angina, a common car...all over the world, is severe chest pain caused by...od to the heart during// physical activity. Curren...
Other Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Breakthrough in Type II Diabetes 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3
...he first objective measurement for CHF. Blood test...diac hormone produced by the heart ventricles in r...re overload. Excellent hormonal marker of ventricu... BNP Test provides meaningful diagnostic informati...
...alvage System offers five different products for l...ese components are cobalt-chrome, ultra high molec...AN products are extensions of Wright Medical Techn... , ,The distal femur consists of a rotating hinge ...
The MOST Options System is designed to enable patients facing severe bone loss of the knee or hip to regain use of their limbs and provides the potential for restoration of function. , ,The system go
...System (OSS) from Biomet Inc. offers the most comp... specifically for orthopaedic surgeons and oncolog...ir patients: significant bone loss, ligamentous de...throplasties, and multiple hip revision arthroplas...
Medicine Products: